# Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
Canonical URL: https://biopharmsignal.com/news/HROW/harrow-to-present-at-william-blair-s-46th-annual-growth-stock-conference-683e18e0
Ticker: HROW
Company: Harrow, Inc.
Source: Harrow, Inc.
Published: 2026-05-27 11:00 EST
## Summary

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,...

## Article Body
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s 46 th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn .

Contact: Mike Biega, Vice President of Investor Relations and Communications mbiega@harrowinc.com 617-913-8890
## Recent Company News
- 2026-07-27 11:00 EST — [Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026](https://biopharmsignal.com/news/HROW/harrow-to-report-second-quarter-2026-financial-results-after-market-close-on-aug-38f34b84) — Source: Harrow, Inc.
- 2026-07-20 12:00 EST — [Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026](https://biopharmsignal.com/news/HROW/samsung-bioepis-and-harrow-present-interim-data-from-a-large-scale-post-marketin-f2b635bb) — Source: Harrow, Inc.
- 2026-07-20 11:00 EST — [Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting](https://biopharmsignal.com/news/HROW/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asr-8b380ee4) — Source: Harrow, Inc.
- 2026-07-01 11:00 EST — [Harrow Announces Commercial Launch of BYOOVIZ® in the United States](https://biopharmsignal.com/news/HROW/harrow-announces-commercial-launch-of-byooviz-in-the-united-states-234ff9de) — Source: Harrow, Inc.
- 2026-06-10 11:00 EST — [Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare](https://biopharmsignal.com/news/HROW/harrow-re-launches-verkazia-cyclosporine-ophthalmic-emulsion-0-1-for-vernal-kera-d7c7e3c9) — Source: Harrow, Inc.
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)